Introducing ONCOSCREEN

Anaxagoras Fotopoulos, EXUS, ONCOSCREEN Project Coordination Team
Dimitra Dionysiou, ICCS, ONCOSCREEN Technical Coordination Team

HaDEA Info-Day: EU Funding Programmes for Health and Digital Transformation



Tuesday 14.05.2024











ONCOSCREEN at a glance...



- 48 Months
- **38** Partners
- 16 Different Countries
- 14 Industrial partners & SMEs
- 11 Technical Solutions
- 10 Research partners
 - 7 Medical science partners & experts in cancer research
- 4 Novel CRC Diagnostics solutions
- **3** Cancer patient associations
- **2** Gastrointestinal & Digestive Oncology Associations
- 2 Policy Makers

4000 + Clinical Trial Subjects



Total cost

€12,972,077





Technical Coordinator



ONCOSCREEN Overall Objectives



To provide a multi-tier, CRC risk-based stratification methodology on target population groups, based on genetic prevalence, socio economic status, environmental stressors, behavioral factors, gender aspects, educational background, urbanization inequalities both between and within EU countries.

To develop novel, non-invasive, easy-to-use, low-cost, CRC screening technologies of high sensitivity and specificity for early polyp indication, detection, classification and personalized risk status stratification

To enhance existing methodologies for precise CRC detection from clinicians and evidence-based decision making from Policy makers, through Al-based integrated diagnostics and analytics


To design and evaluate a novel multi-tier CRC screening program for target populations through lab validation and clinical trials in EU countries and regions.

To assess feasibility of adoption and design viable pathways for EU wide uptake of ONCOSCREEN solutions in everyday medical practice for wide-population CRC screening.

To enhance citizen awareness, participation and acceptance of CRC screening programs

ONCOSCREEN Expected Outputs





Where we stand now?

- Website and social media are up and running
- Common Data Management Plan defined
- > First version of the Co-Designed System Architecture system architecture completed
- First version of end-user and technical requirements completed (Co-Design)
- SOPs for diagnostic devices ready
- > First version of tools is ready, 2 Laboratory Integration Tests completed
- Documents for ethics approval of the clinical study submitted
- Clustering Activities with other projects in the frame of the 'Prevention and Early Detection (Screening)' Cluster









Thank you



Anaxagoras Fotopoulos a.fotopoulos@exus.ai



Dimitra Dionysiou dimitra.dionysiou@iccs.gr









ONCOSCREEN

















































































Funded by the European Union